Oligosaccharide Trial Sees Improvement in Alzheimer’s

amyloid
amyloid
Researchers plan to continue to evaluate the efficacy of oligomannurarate 900 mg in a phase III trial.

Shooting at the same target but with a different kind of arrow, Chinese researchers have shown that an oligosaccharide that binds more than one region of amyloid-β (Aβ) enhances clearance of the protein from the brain and improves cognition among patients with mild to moderate Alzheimer’s disease (AD).

“Family members perceived improvements after 24 weeks [of] treatments,” Shifu Xiao, MD, PhD, from Shanghai Jiao Tong University School of Medicine in China told attendees here at the 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD).

READ FULL ARTICLE Curated publisher From Med Scape